Novel Benzimidazole/Hydrazone Derivatives as Promising Anticancer Lead Compounds: Design, Synthesis, and Molecular Docking Study | ||||
| Journal of advanced Biomedical and Pharmaceutical Sciences | ||||
| Article 1, Volume 3, Issue 2, April 2020, Page 45-52 PDF (1.29 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jabps.2020.21160.1064 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Martha M. Morcoss1; El Shimaa M. N. Abdelhafez  2; Hamdy M. Abdel-Rahman1, 3; Mohamed Abdel-Aziz2; Dalal A. Abou El-Ella4
| ||||
| 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University, 62513 New Beni Suef, Egypt | ||||
| 2Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt | ||||
| 3Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, 71526 Assiut, Egypt | ||||
| 4Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, 11566 Abbassia, Cairo, Egypt | ||||
| Abstract | ||||
| A novel series of benzimidazole-hydrazone derivatives was designed and synthesized as a potential anti-cancer agents. The structure of the target compounds was assured using different spectroscopic methods such as IR , 1H NMR, 13C NMR and elemental analysis. These new compounds were examined and evaluated for their antiproliferative activities against 60 different cell lines. Combination of benzimidazole scaffold with hydrazone group exhibited promising anti-cancer activity. Compounds 3a and 3b showed significant activity against different cancer cells lines between 50-84 % of growth inhibition. A molecular modeling study for compounds 3a and 3b into VEGFR-2 active site was performed with reasonable docking scores. | ||||
| Keywords | ||||
| Benzimidazole; hydrazone; Anti-cancer; Molecular docking | ||||
|
Statistics Article View: 1,304 PDF Download: 1,378 |
||||
